XTALPI (02228.HK): AI drug discovery pact with Pierre Fabre
- The pact covers several oncology programmes and may extend to dermatology and rare diseases, aiming to speed up identification of quality clinical candidates.
- XtalPi will design and deliver novel small molecules against undisclosed targets, while Pierre Fabre leads later clinical and commercial development.
NewTimeSpace News: On 9 November 2026, XtalPi Holdings Limited (Stock Code: 02228) said its wholly-owned units QuantumPharm Limited and XtalPi Shanghai signed a research collaboration with Pierre Fabre Médicament SAS to discover novel clinical candidates across several oncology programmes, potentially extending to dermatology and rare diseases.
The announcement shows XtalPi will use its integrated AI and robotics platform to design and deliver small-molecule therapies against undisclosed targets from scratch, while Pierre Fabre contributes disease biology, discovery and clinical expertise to pick and advance the best compounds and will lead later clinical and commercial development. The deal includes upfront, milestone and downstream payments.
